These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11018 related articles for article (PubMed ID: 14691295)

  • 1. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
    Weber A; Hengge UR; Urbanik D; Markwart A; Mirmohammadsaegh A; Reichel MB; Wittekind C; Wiedemann P; Tannapfel A
    Lab Invest; 2003 Dec; 83(12):1771-6. PubMed ID: 14691295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
    Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
    Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
    Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.
    Calipel A; Mouriaux F; Glotin AL; Malecaze F; Faussat AM; Mascarelli F
    J Biol Chem; 2006 Apr; 281(14):9238-50. PubMed ID: 16452469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Episodic Src activation in uveal melanoma revealed by kinase activity profiling.
    Maat W; el Filali M; Dirks-Mulder A; Luyten GP; Gruis NA; Desjardins L; Boender P; Jager MJ; van der Velden PA
    Br J Cancer; 2009 Jul; 101(2):312-9. PubMed ID: 19568237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
    Huntington JT; Shields JM; Der CJ; Wyatt CA; Benbow U; Slingluff CL; Brinckerhoff CE
    J Biol Chem; 2004 Aug; 279(32):33168-76. PubMed ID: 15184373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors.
    Tannapfel A; Vomschloss S; Karhoff D; Markwarth A; Hengge UR; Wittekind C; Arnold R; Hörsch D
    Am J Clin Pathol; 2005 Feb; 123(2):256-60. PubMed ID: 15842051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
    Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
    Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
    Thomas NE
    Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.
    Van Raamsdonk CD; Bezrookove V; Green G; Bauer J; Gaugler L; O'Brien JM; Simpson EM; Barsh GS; Bastian BC
    Nature; 2009 Jan; 457(7229):599-602. PubMed ID: 19078957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The T1799A point mutation is present in posterior uveal melanoma.
    Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
    Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of BRAF mutation in primary uveal melanoma.
    Cohen Y; Goldenberg-Cohen N; Parrella P; Chowers I; Merbs SL; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2876-8. PubMed ID: 12824225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
    Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
    Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 551.